Shiyun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shiyun Chen has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Yong Zhang
Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
18 shared publications Yangbo Hu
State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China
13 shared publications- Yangbo Hu
Chinese Academy of Sciences
13 shared publications Pei Lu
CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
11 shared publicationsBaoyu Yang
Key Laboratory of Agricultural and Environmental Microbiology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
6 shared publicationsLamei Li
Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
6 shared publications
Latest Publications
- Open Access
miR-26a-5p Activates Antiviral Innate Immunity via Direct Binding and Activation of RIG-I
Emerging evidence has revealed the critical roles of microRNAs (miRNAs) in the regulation of innate immune responses. Nevertheless, it remains poorly understood whether specific miRNAs can directly modulate retinoic acid-inducible gene I (RIG-I), a principal sensor of cytoplasmic viral RNA and a key initiator of antiviral innate immunity. In this study, we identified miR-26a-5p as a potent activator of the innate antiviral immune responses. Notably, this activation operates independently of the canonical miRNA pathways of translational repression and mRNA degradation. Instead, we demonstrated that miR-26a-5p exerts its immunostimulatory effects by specifically binding to the RIG-I receptor. RNA immunoprecipitation and RNA pull-down assays confirmed a direct physical interaction between miR-26a-5p and the RIG-I protein. Subsequent site-directed mutagenesis verified that an AU-rich motif is critical for miR-26a-5p-driven RIG-I activation. Viral challenge experiments demonstrated that miR-26a-5p confers broad-spectrum, RIG-I-dependent antiviral activity against both DNA viruses (herpes simplex virus type 1 and Kaposi’s sarcoma-associated herpesvirus) and RNA viruses (influenza A virus and respiratory syncytial virus). Collectively, our study indicates that miR-26a-5p may serve as a ligand that binds to and activates the RIG-I receptor. This discovery uncovers a previously unrecognized mechanism through which host miRNAs regulate antiviral innate immunity.
Open AccessmiR-26a-5p Activates Antiviral Innate Immunity via Direct Binding and Activation of RIG-I
Emerging evidence has revealed the critical roles of microRNAs (miRNAs) in the regulation of innate immune responses. Nevertheless, it remains poorly understood whether specific miRNAs can directly modulate retinoic acid-inducible gene I (RIG-I), a principal sensor of cytoplasmic viral RNA and a key initiator of antiviral innate immunity. In this study, we identified miR-26a-5p as a potent activator of the innate antiviral immune responses. Notably, this activation operates independently of the canonical miRNA pathways of translational repression and mRNA degradation. Instead, we demonstrated that miR-26a-5p exerts its immunostimulatory effects by specifically binding to the RIG-I receptor. RNA immunoprecipitation and RNA pull-down assays confirmed a direct physical interaction between miR-26a-5p and the RIG-I protein. Subsequent site-directed mutagenesis verified that an AU-rich motif is critical for miR-26a-5p-driven RIG-I activation. Viral challenge experiments demonstrated that miR-26a-5p confers broad-spectrum, RIG-I-dependent antiviral activity against both DNA viruses (herpes simplex virus type 1 and Kaposi’s sarcoma-associated herpesvirus) and RNA viruses (influenza A virus and respiratory syncytial virus). Collectively, our study indicates that miR-26a-5p may serve as a ligand that binds to and activates the RIG-I receptor. This discovery uncovers a previously unrecognized mechanism through which host miRNAs regulate antiviral innate immunity.
- Open Access
- 15 June 2026
- Published by Elsevier in Cell Insight
- Vol. 5 (4) , 100342
Beyond adaptive immunity: Functional diversity of the type III-A CRISPR-Cas system in Mycobacterium tuberculosis
- 15 June 2026
- Published by Elsevier in Cell Insight
- Vol. 5 (4) , 100342
Open AccessBeyond adaptive immunity: Functional diversity of the type III-A CRISPR-Cas system in Mycobacterium tuberculosis
- Open Access
- 24 February 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (5)
Orn-mediated c-di-GMP regulates the CRISPR-Cas system to confer stress response in Mycobacterium tuberculosis
Mycobacterium tuberculosis (Mtb) possesses a type III-A CRISPR-Cas system and has anti-plasmid immune activity. However, whether this system exerts other additional functions remains to be characterized. Here, we investigated the in vivo roles of the Mtb CRISPR-Cas system. We show that this system is transcriptionally dependent and exhibits limited ability to counteract exogenous nucleic acids, primarily through the Csm6 protein rather than the Cas10 HD domain. We further demonstrate that this system plays a role in mitigating oxidative stress and antibiotic treatment, a function mainly mediated by the Cas10 HD domain. Importantly, through transposon library screening, we identified oligoribonuclease (Orn) as a regulatory protein of the Mtb CRISPR-Cas system. Deletion of the orn gene resulted in elevated c-di-GMP levels. A subsequent biotin-labeled c-di-GMP pull-down assay identified the transcriptional regulator Rv3058. Knockdown of rv3058 significantly increased cas6 promoter activity, and its transcriptional repressor function was directly modulated by c-di-GMP. This regulatory pathway enhances stress defense by activating multiple protective pathways, including DNA repair, cell envelope maintenance, and iron homeostasis regulation. Together, we conclude that the regulation of the CRISPR-Cas system by Orn-mediated c-di-GMP contributes to oxidative and antibiotic stress responses in Mtb.
- 24 February 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (5)
Open AccessOrn-mediated c-di-GMP regulates the CRISPR-Cas system to confer stress response in Mycobacterium tuberculosis
Mycobacterium tuberculosis (Mtb) possesses a type III-A CRISPR-Cas system and has anti-plasmid immune activity. However, whether this system exerts other additional functions remains to be characterized. Here, we investigated the in vivo roles of the Mtb CRISPR-Cas system. We show that this system is transcriptionally dependent and exhibits limited ability to counteract exogenous nucleic acids, primarily through the Csm6 protein rather than the Cas10 HD domain. We further demonstrate that this system plays a role in mitigating oxidative stress and antibiotic treatment, a function mainly mediated by the Cas10 HD domain. Importantly, through transposon library screening, we identified oligoribonuclease (Orn) as a regulatory protein of the Mtb CRISPR-Cas system. Deletion of the orn gene resulted in elevated c-di-GMP levels. A subsequent biotin-labeled c-di-GMP pull-down assay identified the transcriptional regulator Rv3058. Knockdown of rv3058 significantly increased cas6 promoter activity, and its transcriptional repressor function was directly modulated by c-di-GMP. This regulatory pathway enhances stress defense by activating multiple protective pathways, including DNA repair, cell envelope maintenance, and iron homeostasis regulation. Together, we conclude that the regulation of the CRISPR-Cas system by Orn-mediated c-di-GMP contributes to oxidative and antibiotic stress responses in Mtb.
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (2)
Bacteriophage deploys a RecA-dependent nuclease to inhibit Staphylococcus aureus replication and promote phage propagation
Bacteriophages have evolved diverse strategies to manipulate host processes, yet the molecular mechanisms employed by phage-encoded effector proteins remain poorly understood. Here, we identify Gp16, an early-expressed protein from Staphylococcus aureus phage ΦNM1, as a RecA-dependent nuclease that plays a dual role in host inhibition and phage propagation. Gp16 is rapidly expressed upon infection, and its overexpression alone is sufficient to inhibit bacterial growth where deletion of gp16 severely impairs phage DNA replication, progeny production, and host cell lysis, underscoring its essential role in the phage life cycle. Structural modeling predicts Gp16 is a nuclease, and its overexpression induces DNA condensation in vivo. Biochemical and cellular analyses show that Gp16 interacts with the host RecA protein to inhibit growth, and functions as a nickase in vitro, requiring the catalytic cysteine C181 for DNA cleavage. RecA further enhances its cleavage activity. During phage infection, RecA activation is required for efficient phage propagation, while Gp16 concurrently suppresses host DNA replication and promotes DNA condensation, thereby facilitating phage replication. Together, these findings reveal a previously unrecognized strategy in which a phage-encoded nuclease exploits the host RecA machinery to couple host suppression with productive phage propagation.
- 14 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (2)
Open AccessBacteriophage deploys a RecA-dependent nuclease to inhibit Staphylococcus aureus replication and promote phage propagation
Bacteriophages have evolved diverse strategies to manipulate host processes, yet the molecular mechanisms employed by phage-encoded effector proteins remain poorly understood. Here, we identify Gp16, an early-expressed protein from Staphylococcus aureus phage ΦNM1, as a RecA-dependent nuclease that plays a dual role in host inhibition and phage propagation. Gp16 is rapidly expressed upon infection, and its overexpression alone is sufficient to inhibit bacterial growth where deletion of gp16 severely impairs phage DNA replication, progeny production, and host cell lysis, underscoring its essential role in the phage life cycle. Structural modeling predicts Gp16 is a nuclease, and its overexpression induces DNA condensation in vivo. Biochemical and cellular analyses show that Gp16 interacts with the host RecA protein to inhibit growth, and functions as a nickase in vitro, requiring the catalytic cysteine C181 for DNA cleavage. RecA further enhances its cleavage activity. During phage infection, RecA activation is required for efficient phage propagation, while Gp16 concurrently suppresses host DNA replication and promotes DNA condensation, thereby facilitating phage replication. Together, these findings reveal a previously unrecognized strategy in which a phage-encoded nuclease exploits the host RecA machinery to couple host suppression with productive phage propagation.
- 19 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (114) , eadk0853
Human OCEL1 senses bacterial infection to unlock inflammatory responses
Processes that control tissue inflammation are essential to restore homeostasis after infection. The transcription factor NF-κB plays a central role in coordinating inflammation, but the mechanisms that regulate NF-κB signaling are not fully understood. Here, we identify OCEL1 ( occludin/ELL domain containing 1 ) as a negative regulator of NF-κB signaling. In the absence of infection, human OCEL1 bound to the LZ domain of NEMO (NF-κB essential modulator) and inhibited TRAF6-mediated K63-linked polyubiquitination, suppressing NF-κB signaling. During infection, OCEL1-mediated negative regulation of NF-κB signaling was impaired by FK506-binding protein bacterial peptidyl-prolyl cis/trans isomerases, which bound to OCEL1 in an amino-terminal palindromic proline–rich element (PPE) and promoted its degradation. Mice expressing a mutant version of the human OCEL1 PPE had dampened inflammation and increased susceptibility to Pseudomonas aeruginosa infection. Thus, the PPE of human OCEL1 senses bacterial infection, and its degradation releases the suppression of NF-κB signaling and promotes inflammation.
- 19 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (114) , eadk0853
Human OCEL1 senses bacterial infection to unlock inflammatory responses
Processes that control tissue inflammation are essential to restore homeostasis after infection. The transcription factor NF-κB plays a central role in coordinating inflammation, but the mechanisms that regulate NF-κB signaling are not fully understood. Here, we identify OCEL1 ( occludin/ELL domain containing 1 ) as a negative regulator of NF-κB signaling. In the absence of infection, human OCEL1 bound to the LZ domain of NEMO (NF-κB essential modulator) and inhibited TRAF6-mediated K63-linked polyubiquitination, suppressing NF-κB signaling. During infection, OCEL1-mediated negative regulation of NF-κB signaling was impaired by FK506-binding protein bacterial peptidyl-prolyl cis/trans isomerases, which bound to OCEL1 in an amino-terminal palindromic proline–rich element (PPE) and promoted its degradation. Mice expressing a mutant version of the human OCEL1 PPE had dampened inflammation and increased susceptibility to Pseudomonas aeruginosa infection. Thus, the PPE of human OCEL1 senses bacterial infection, and its degradation releases the suppression of NF-κB signaling and promotes inflammation.
- Open Access
- 9 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice
Influenza virus infection remains a major global health problem and requires a universal vaccine with broad protection against different subtypes as well as a rapid-response vaccine to provide immediate protection in the event of an epidemic outbreak. Here, we show that intranasal administration of probiotic Escherichia coli Nissle 1917 activates innate immunity in the respiratory tract and provides immediate protection against influenza virus infection within 1 day. Based on this vehicle, a recombinant strain is engineered to express and secret five tandem repeats of the extracellular domain of matrix protein 2 from different influenza virus subtypes. Intranasal vaccination with this strain induces durable humoral and mucosal responses in the respiratory tract, and provides broad protection against the lethal challenge of divergent influenza viruses in female BALB/c mice. Our findings highlight a promising delivery platform for developing mucosal vaccines that provide immediate and sustained protection against respiratory pathogens.
- 9 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessEngineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice
Influenza virus infection remains a major global health problem and requires a universal vaccine with broad protection against different subtypes as well as a rapid-response vaccine to provide immediate protection in the event of an epidemic outbreak. Here, we show that intranasal administration of probiotic Escherichia coli Nissle 1917 activates innate immunity in the respiratory tract and provides immediate protection against influenza virus infection within 1 day. Based on this vehicle, a recombinant strain is engineered to express and secret five tandem repeats of the extracellular domain of matrix protein 2 from different influenza virus subtypes. Intranasal vaccination with this strain induces durable humoral and mucosal responses in the respiratory tract, and provides broad protection against the lethal challenge of divergent influenza viruses in female BALB/c mice. Our findings highlight a promising delivery platform for developing mucosal vaccines that provide immediate and sustained protection against respiratory pathogens.
- Open Access
- 12 June 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (6) , e0067924
Phage protein Gp11 blocks Staphylococcus aureus cell division by inhibiting peptidoglycan biosynthesis
Phages and bacteria have a long history of co-evolution. However, these dynamics of phage-host interactions are still largely unknown; identification of phage inhibitors that remodel host metabolism will provide valuable information for target development for antimicrobials. Here, we perform a comprehensive screen for early-gene products of ΦNM1 that inhibit cell growth in Staphylococcus aureus . A small membrane protein, Gp11, with inhibitory effects on S. aureus cell division was identified. A bacterial two-hybrid library containing 345 essential S. aureus genes was constructed to screen for targets of Gp11, and Gp11 was found to interact with MurG and DivIC. Defects in cell growth and division caused by Gp11 were dependent on MurG and DivIC, which was further confirmed using CRISPRi hypersensitivity assay. Gp11 interacts with MurG, the protein essential for cell wall formation, by inhibiting the production of lipid II to regulate peptidoglycan (PG) biosynthesis on the cell membrane. Gp11 also interacts with cell division protein DivIC, an essential part of the division machinery necessary for septal cell wall assembly, to disrupt the recruitment of division protein FtsW. Mutations in Gp11 result in loss of its ability to cause growth defects, whereas infection with phage in which the gp11 gene has been deleted showed a significant increase in lipid II production in S. aureus . Together, our findings reveal that a phage early-gene product interacts with essential host proteins to disrupt PG biosynthesis and block S. aureus cell division, suggesting a potential pathway for the development of therapeutic approaches to treat pathogenic bacterial infections. IMPORTANCE: Understanding the interplay between phages and their hosts is important for the development of novel therapies against pathogenic bacteria. Although phages have been used to control methicillin-resistant Staphylococcus aureus infections, our knowledge related to the processes in the early stages of phage infection is still limited. Owing to the fact that most of the phage early proteins have been classified as hypothetical proteins with uncertain functions, we screened phage early-gene products that inhibit cell growth in S. aureus , and one protein, Gp11, selectively targets essential host genes to block the synthesis of the peptidoglycan component lipid II, ultimately leading to cell growth arrest in S. aureus . Our study provides a novel insight into the strategy by which Gp11 blocks essential host cellular metabolism to influence phage-host interaction. Importantly, dissecting the interactions between phages and host cells will contribute to the development of new and effective therapies to treat bacterial infections.
- 12 June 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (6) , e0067924
Open AccessPhage protein Gp11 blocks Staphylococcus aureus cell division by inhibiting peptidoglycan biosynthesis
Phages and bacteria have a long history of co-evolution. However, these dynamics of phage-host interactions are still largely unknown; identification of phage inhibitors that remodel host metabolism will provide valuable information for target development for antimicrobials. Here, we perform a comprehensive screen for early-gene products of ΦNM1 that inhibit cell growth in Staphylococcus aureus . A small membrane protein, Gp11, with inhibitory effects on S. aureus cell division was identified. A bacterial two-hybrid library containing 345 essential S. aureus genes was constructed to screen for targets of Gp11, and Gp11 was found to interact with MurG and DivIC. Defects in cell growth and division caused by Gp11 were dependent on MurG and DivIC, which was further confirmed using CRISPRi hypersensitivity assay. Gp11 interacts with MurG, the protein essential for cell wall formation, by inhibiting the production of lipid II to regulate peptidoglycan (PG) biosynthesis on the cell membrane. Gp11 also interacts with cell division protein DivIC, an essential part of the division machinery necessary for septal cell wall assembly, to disrupt the recruitment of division protein FtsW. Mutations in Gp11 result in loss of its ability to cause growth defects, whereas infection with phage in which the gp11 gene has been deleted showed a significant increase in lipid II production in S. aureus . Together, our findings reveal that a phage early-gene product interacts with essential host proteins to disrupt PG biosynthesis and block S. aureus cell division, suggesting a potential pathway for the development of therapeutic approaches to treat pathogenic bacterial infections. IMPORTANCE: Understanding the interplay between phages and their hosts is important for the development of novel therapies against pathogenic bacteria. Although phages have been used to control methicillin-resistant Staphylococcus aureus infections, our knowledge related to the processes in the early stages of phage infection is still limited. Owing to the fact that most of the phage early proteins have been classified as hypothetical proteins with uncertain functions, we screened phage early-gene products that inhibit cell growth in S. aureus , and one protein, Gp11, selectively targets essential host genes to block the synthesis of the peptidoglycan component lipid II, ultimately leading to cell growth arrest in S. aureus . Our study provides a novel insight into the strategy by which Gp11 blocks essential host cellular metabolism to influence phage-host interaction. Importantly, dissecting the interactions between phages and host cells will contribute to the development of new and effective therapies to treat bacterial infections.
- Open Access
- 26 April 2022
- Published by American Society for Microbiology in mBio
- Vol. 13 (2) , e0334321
A Feedback Regulatory Loop Containing McdR and WhiB2 Controls Cell Division and DNA Repair in Mycobacteria
Drug-resistant M. tuberculosis poses a threat to the control and prevention of tuberculosis (TB) worldwide. Thus, there is a need to identify the mechanisms enabling M. tuberculosis to adapt and grow under drug-induced stress.
- 26 April 2022
- Published by American Society for Microbiology in mBio
- Vol. 13 (2) , e0334321
Open AccessA Feedback Regulatory Loop Containing McdR and WhiB2 Controls Cell Division and DNA Repair in Mycobacteria
Drug-resistant M. tuberculosis poses a threat to the control and prevention of tuberculosis (TB) worldwide. Thus, there is a need to identify the mechanisms enabling M. tuberculosis to adapt and grow under drug-induced stress.
- Open Access
Insulated expression of periplasmic uricase in E. coli Nissle 1917 for the treatment of hyperuricemia
Hyperuricemia is a prevalent disease worldwide that is characterized by elevated urate levels in the blood owing to purine metabolic disorders, which can result in gout and comorbidities. As approximately one-third of urate is excreted by the small intestine and cleared by intestinal microorganisms, modulating the gut microbiota could be an attractive approach for hyperuricemia and gout treatment. In this study, we engineered a probiotic E. coli Nissle 1917 (EcN) strain, EcN C6, which expresses periplasmic uricase at an “insulated site”, for urate degeneration. Oral administration of EcN C6 successfully alleviated hyperuricemia, related symptom and gut microbiota in a purine-rich food-induced hyperuricemia rat model and a uox -knockout mouse model. Importantly, the expression of periplasmic uricase in the insulated site did not influence the probiotic properties or global gene transcription of EcN, suggesting that EcN C6 is a safe, effective and low cost therapeutic candidate for hyperuricemia treatment.
Open AccessInsulated expression of periplasmic uricase in E. coli Nissle 1917 for the treatment of hyperuricemia
Hyperuricemia is a prevalent disease worldwide that is characterized by elevated urate levels in the blood owing to purine metabolic disorders, which can result in gout and comorbidities. As approximately one-third of urate is excreted by the small intestine and cleared by intestinal microorganisms, modulating the gut microbiota could be an attractive approach for hyperuricemia and gout treatment. In this study, we engineered a probiotic E. coli Nissle 1917 (EcN) strain, EcN C6, which expresses periplasmic uricase at an “insulated site”, for urate degeneration. Oral administration of EcN C6 successfully alleviated hyperuricemia, related symptom and gut microbiota in a purine-rich food-induced hyperuricemia rat model and a uox -knockout mouse model. Importantly, the expression of periplasmic uricase in the insulated site did not influence the probiotic properties or global gene transcription of EcN, suggesting that EcN C6 is a safe, effective and low cost therapeutic candidate for hyperuricemia treatment.
- Open Access
- 18 January 2022
- Published by Wiley in Molecular Microbiology
- Vol. 117 (4) , 886-906
TypeIIIsecretion byYersinia pseudotuberculosisis reliant upon an authentic N‐terminalYscXsecretor domain
YscX was discovered as an essential part of theYersiniatype III secretion system about 20 years ago. It is required for substrate secretion and is exported itself. Despite this central role, its precise function and mode of action remain unknown. In order to address this knowledge gap, this present study refocused attention on YscX to build on the recent advances in the understanding of YscX function. Our experiments identified an N‐terminal secretion domain in YscX promoting its secretion, with the first five codons constituting a minimal signal capable of promoting secretion of the signal less β‐lactamase reporter. Replacing the extreme YscX N‐terminus with known secretion signals of other Ysc‐Yop substrates revealed that the YscX N‐terminal segment contains non‐redundant information needed for YscX function. Further, bothin cisdeletion of the YscX N‐terminus in the virulence plasmid and ectopic expression of epitope‐tagged YscX variants again lead to stable YscX production but not type III secretion of Yop effector proteins. Mislocalisation of the needle components, SctI and SctF, accompanied this general defect in Yops secretion. Hence, a coupling exists between YscX secretion permissiveness and the assembly of an operational secretion system.
- 18 January 2022
- Published by Wiley in Molecular Microbiology
- Vol. 117 (4) , 886-906
Open AccessTypeIIIsecretion byYersinia pseudotuberculosisis reliant upon an authentic N‐terminalYscXsecretor domain
YscX was discovered as an essential part of theYersiniatype III secretion system about 20 years ago. It is required for substrate secretion and is exported itself. Despite this central role, its precise function and mode of action remain unknown. In order to address this knowledge gap, this present study refocused attention on YscX to build on the recent advances in the understanding of YscX function. Our experiments identified an N‐terminal secretion domain in YscX promoting its secretion, with the first five codons constituting a minimal signal capable of promoting secretion of the signal less β‐lactamase reporter. Replacing the extreme YscX N‐terminus with known secretion signals of other Ysc‐Yop substrates revealed that the YscX N‐terminal segment contains non‐redundant information needed for YscX function. Further, bothin cisdeletion of the YscX N‐terminus in the virulence plasmid and ectopic expression of epitope‐tagged YscX variants again lead to stable YscX production but not type III secretion of Yop effector proteins. Mislocalisation of the needle components, SctI and SctF, accompanied this general defect in Yops secretion. Hence, a coupling exists between YscX secretion permissiveness and the assembly of an operational secretion system.